Navigation Links
Topical treatment for cold sores achieves efficacy of oral drugs; represents paradigm shift
Date:10/28/2008

WASHINGTON, D.C. (October 28, 2008) Scientists at NanoBio Corporation have demonstrated for the first time in humans that a novel topical treatment for cold sores (herpes labialis), NB-001, speeds healing of lesions as effectively as the leading oral systemic drugs but without safety or toxicity concerns.

The new data provide the first proof of principle that a topical agent can attain equivalent efficacy rates to oral systemic drugs, according to the NanoBio scientists. Topical treatments are widely considered inferior to oral systemic treatments because they fail to penetrate to the site of infection with adequate drug levels required to subdue infections.

In the study of 482 patients, NB-001 healed lesions 1.3 days faster than placebo as measured by investigators (P=0.006). Results of the randomized, double-blind, placebo-controlled, phase 2b trial are being presented at the 48th annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)/Infectious Diseases Society of America (IDSA) 46th annual meeting in Washington, D.C.

NB-001 was well tolerated, without safety concerns or adverse events, and was not systemically absorbed. "NB-001 challenges the conventional wisdom that topical therapies are less effective, because NB-001 directly accesses the site of infection in the dermis and epidermis instead of remaining on top of the skin," said James R. Baker, Jr., M.D., founder and chairman of NanoBio Corp. "NB-001 employs a physical mode of action to disrupt the outer membranes of pathogens and prompt viral lysis, essentially killing on contact."

The study also suggests that the physical mode of action of NB-001 significantly reduces the likelihood that pathogens will develop resistance to the biocidal effect of the topical lotion.

"These characteristics make NB-001 an ideal candidate for first-line treatment with the potential for widespread use across a broad range of patients," said Mary Fla
'/>"/>

Contact: Becky Levine
blevine@medthink.com
919-786-4918
MedThink Communications
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Perrigo Company Announces FDA Approval for Ciclopirox Topical Solution
2. Perrigo Company Announces FDA Approval for Ciclopirox Topical Solution
3. Voltaren(R) Gel Receives US Regulatory Approval as the First Approved Topical Prescription Treatment for Pain Associated with Osteoarthritis
4. Warner Chilcott and NexMed Sign U.S. Collaboration for Topical Alprostadil Treatment for Erectile Dysfunction
5. Topical treatment for age spots, from Harvard Womens Health Watch
6. Summit VetPharm Introduces New Feline Topicals Vectra(TM) for Cats & Kittens and Vectra(TM) for Cats
7. International Federation of Sports Medicine Selects Celadrin(R) Topical Cream as its First and Only Official Joint and Muscle Topical Cream
8. ZARS Pharma Announces Worldwide License Agreement With Galderma Pharma S.A. for Pliaglis(TM), a Topical Local Anesthetic
9. Topical Cream Treats Precancerous Lesions of Vulva
10. ImQuest Presents New Anti-HIV Drug and Topical Microbicide Development Results on Lead Pyrimidinedione Products IQP-0410 and IQP-0528
11. Fougera First-to-Market With Calcipotriene Topical Solution 0.005% (Rx) (Scalp Solution)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/18/2014)... 18, 2014 Cristcot Inc., a ... and commercialization of specialized drug delivery systems, today ... Cristcot a patent for the technology, which encompasses ... , The patent was awarded to the ... have been assigned to Cristcot Inc. The patented ...
(Date:11/18/2014)... 18, 2014 Medicationdiscountcard.com's ... adding to the company's reputation for helping consumers ... blog has to offer at http://blog.medicationdiscountcard.com/ . ... information concerning the Affordable Care Act and the ... inform the public about a variety of prescription ...
(Date:11/18/2014)... Thompson HealthDay Reporter ... antibody drug could prove effective at lowering LDL ("bad") ... cholesterol-lowering statin medications. That,s the conclusion of a ... annual meeting in Chicago. The drug, alirocumab, outperformed ... used alternative to statins, Zetia, said lead researcher Dr. ...
(Date:11/18/2014)... (HealthDay News) -- Women who started smoking at a ... severe menstrual pain, a new study suggests. About ... smoking has been suspected as a risk factor for ... authors of the new study said. The researchers ... long-term study of women,s health in Australia. About 14 ...
(Date:11/18/2014)... November 18, 2014 Global ... using the telehealth platform to bring quality healthcare ... this passion, GPT created Global Partnership for TeleHealth ... already existing telehealth network. GPTM focuses specifically ... overseas, and disaster relief organizations. , ...
Breaking Medicine News(10 mins):Health News:Japanese Patent Office Grants Patent to Cristcot Inc. 2Health News:Medicationdiscountcard.com Building Virtual Library of Resources to Help Consumers Navigate Healthcare Landscape 2Health News:Experimental Cholesterol-Lowering Drug Effective, Study Reports 2Health News:Experimental Cholesterol-Lowering Drug Effective, Study Reports 3Health News:Study Ties Teen Smoking to Risk of Severe Menstrual Cramps 2Health News:Global Partnership for TeleHealth (GPT) is Focused on Using the telehealth Platform to Bring Quality Healthcare to Populations in Need Worldwide 2
... from Shropshire and parts of Wales. Breast cancer patients from ... but Welsh women get it for free. // ,This ... to pay for Herceptin for early stage breast cancer sufferers ... the welsh as all Welsh Local Health Boards have agreed ...
... in the capital of Zagreb it was revealed that a dead ... flu virus. //, ,The location of the dead swan was ... weekend. Tests confirmed that the dead bird had contracted the H5 ... it was the lethal H5N1 strain would be released on Sunday ...
... simulated investment game, a study, intending to investigate ... working //collectively in a team, revealed stark observations ... conducted by the University of Erfurt team, found ... when ‘punishments’ became a form of motivation. Psychologists ...
... nations should be prepared to pledge more money to combat ... ,Western and Asian donors had pledged $1.9 billion ... flu and improve containment and prevention methods in 12 countries, ... spreading across the world through migratory birds, including infections in ...
... should avoid exposure to the fumes of solvents used ... and lacquers//, could give rise to allergies in young ... Germany's environmental agency. ,Pregnant women should leave ... stay clear of the work area altogether. ...
... has warned the nation's betel-nut chewers of the increased ... habits like smoking and drinking. ,According to ... National Health Research Institute when betel nut chewing was ... cancer of the esophagus was about 195 times higher ...
Cached Medicine News:Health News:Free Herceptin Treatment for Those Who Live Over the Welsh Border 2Health News:Motivation Yardstick: Rewards or Punishment? Discover the Superior Performance Trigger 2Health News:Cancer Risks for Betel Nut Chewers 2
(Date:11/18/2014)... , Nov. 18, 2014  A new global ... finds that a large majority of the general public ... (84%), a devastating disease that is responsible for 1.59 ... cancers combined 1,2,4 . The "Any One Any Lung" ... about the widespread impact of lung cancer, but also ...
(Date:11/18/2014)... -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX ) ... receipt of approval from the U.S. Food and Drug ... IMPLANT ® Saline-filled Breast Implant for ... augmentation implants. The FDA approval of the IDEAL IMPLANT ... and data including a U.S. clinical trial that began ...
(Date:11/18/2014)... Tocagen Inc. today announced that ... free survival at six months for recurrent high grade ... FC, compared to published benchmarks. HGG includes glioblastoma, the ... The data were delivered in an oral presentation at the ... of the Society for Neuro-Oncology (SNO) by Tim ...
Breaking Medicine Technology:Global survey of more than 10,000 adults highlights misperceptions about lung cancer, a disease that kills 1.59 million people annually 2Global survey of more than 10,000 adults highlights misperceptions about lung cancer, a disease that kills 1.59 million people annually 3Global survey of more than 10,000 adults highlights misperceptions about lung cancer, a disease that kills 1.59 million people annually 4Global survey of more than 10,000 adults highlights misperceptions about lung cancer, a disease that kills 1.59 million people annually 5Global survey of more than 10,000 adults highlights misperceptions about lung cancer, a disease that kills 1.59 million people annually 6Valeant Pharmaceuticals And IDEAL IMPLANT Announce FDA And Health Canada Approval To Market Ideal Implant For Cosmetic Breast Augmentation 2Valeant Pharmaceuticals And IDEAL IMPLANT Announce FDA And Health Canada Approval To Market Ideal Implant For Cosmetic Breast Augmentation 3Interim Data Show Increased Median Overall Survival of Recurrent Brain Cancer Patients Treated with Tocagen's Toca 511 & Toca FC, Compared to Published Benchmarks 2Interim Data Show Increased Median Overall Survival of Recurrent Brain Cancer Patients Treated with Tocagen's Toca 511 & Toca FC, Compared to Published Benchmarks 3Interim Data Show Increased Median Overall Survival of Recurrent Brain Cancer Patients Treated with Tocagen's Toca 511 & Toca FC, Compared to Published Benchmarks 4Interim Data Show Increased Median Overall Survival of Recurrent Brain Cancer Patients Treated with Tocagen's Toca 511 & Toca FC, Compared to Published Benchmarks 5
... May 16 Pulmo BioTech Inc. (OTC,Bulletin Board: PLMO.OB) ... Phase I Human Trials with its PulmoBind Molecular Imaging,technology ... The work will be carried out by the Pulmo ... is: "Phase I Study of the Use,of PulmoBind for ...
... -- Results demonstrating that TYKERB and trastuzumab ... survival (PFS), -- Combining TYKERB and trastuzumab ... HER2 receptor may create a more complete HER2 ... alone despite patients,previous treatment with multiple lines of ...
Cached Medicine Technology:Pulmo BioTech Announces Details of the Methodology for its Phase I Human Trials 2Pulmo BioTech Announces Details of the Methodology for its Phase I Human Trials 3GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 2GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 3GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 4GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 5GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 6GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 7
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: